EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
FEB 2022
TABLES
117
PAGES
380
EDITION
19
PRICE
USD 5450
CODE
MCP-6202
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Global Bipolar Disorder Therapeutics Market to Reach US$6.8 Billion by the Year 2026
Bipolar disorder (also manic depression or manic depressive disorder) is a severe double-edged psychiatric illness featuring cyclical mood swings of depression and elation. Bipolar disorder is one of the leading brain diseases causing unusual shift in energy, mood, activity levels, and ability to perform daily activities. Bipolar disorders increase the risk of premature death due to several comorbidities such as diabetes, obesity, and cardiovascular diseases. Bipolar disorder is treated with medication in addition to alternative therapies of electro convulsion, stress reduction and counselling. Global market for bipolar disorder therapeutics maintained growth trajectory during 2020 and 2021 as patient treatment programs remained mostly unperturbed by the pandemic. Patient inflows remained resilient during the pandemic period and care givers maintained their focus on effective treatment regimens for their patients. In countries such as the US, a large increase in anxiety disorders including panic attacks and social anxiety, amongst people was observed which eventually led to increased uptake of treatment and medications for curing the same. Moreover, rising focus of government and healthcare institutes on treating mental health problems is also expected to bode well for the market. With increasing competition in the market and technological developments, researchers are concentrating on first generation antipsychotics to gain better knowledge of their functioning.
Amid the COVID-19 crisis, the global market for Bipolar Disorder Therapeutics estimated at US$5.9 Billion in the year 2022, is projected to reach a revised size of US$6.8 Billion by 2026, growing at a CAGR of 3.1% over the analysis period. Antipsychotic Drugs, one of the segments analyzed in the report, is projected to grow at a 3% CAGR to reach US$3.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anticonvulsants segment is readjusted to a revised 3.9% CAGR for the next 7-year period. This segment currently accounts for a 21.8% share of the global Bipolar Disorder Therapeutics market. Generally prescribed to treat schizophrenia, antipsychotic drugs have a wider relevance in managing bipolar disorders. In bipolar care, antipsychotic drugs are highly preferred in treating periods of psychosis during mania or severe depression. Anticonvulsant drugs aid in the treatment of bipolar disorder and in managing the mania associated with bipolar disorder. Widely prescribed anticonvulsant drugs for bipolar disorder treatment include carbamazepine (Equetro), divalproex sodium (Depakote), lamotrigine (Lamictal), topiramate (Topamax), and valproic acid (Depakene).
The U.S. Market is Estimated at $2.6 Billion in 2022, While China is Forecast to Reach $513.9 Million by 2026
The Bipolar Disorder Therapeutics market in the U.S. is estimated at US$2.6 Billion in the year 2022. The country currently accounts for a 44.35% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$513.9 Million in the year 2026 trailing a CAGR of 4.8% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR while Rest of European market (as defined in the study) will reach US$243.7 Million by the end of the analysis period. North America leads the world bipolar disorder therapeutics market, supported by the strong awareness of the disease condition, existence of leading companies, technological developments, presence of a strong healthcare system, and increasing number of bipolar disorder cases in the region. Asia, led by India and China, is expected to emerge to be the market with strong growth mainly on account of rising prevalence of mental disorders, improving awareness regarding bipolar disorders, and increasing investments by leading companies.
New R&D, product approvals and launches are poised to elevate the prospects of bipolar disorder therapeutics market in the coming years. Recent years saw approval for and roll out of high-quality medications for bipolar disorder. Intra-Cellular Therapies, Alkermes plc and Allergan are some of the companies that have received approvals for their bipolar disorder medications in recent years. While Intra-Cellular Therapies and Alkermes bagged approval for their new drugs, Allergan won the approval for expanded use of Vraylar, which originally received regulatory approval in 2015. In December 2021, Intra-Cellular Therapies bagged the U.S. FDA approval for Caplyta (Lumateperone) compound to treat depressive episodes in patients suffering from bipolar I or bipolar II disorder. Caplyta is currently the one-of-its-kind FDA approved drug to treat depressive episodes emerging from bipolar I or II condition in adults as both monotherapy and adjunctive therapy with either lithium or valproate. Licensed from Bristol-Myers Squibb, Lumateperone is a butyrophenone atypical antipsychotic compound originally developed by Intra-Cellular to treat schizophrenia. Intra-Cellular developed Lumateperone under the name Caplyta for Bipolar Depression and other neurological indications. It is expected that Caplyta medication may evolve into a core treatment option for physicians treating the bipolar condition. In June 2021, Alkermes plc received the U.S. FDA approval for LYBALVI™ (olanzapine and samidorphan) for the treatment of adults with bipolar I disorder. The medication is intended for use as a maintenance monotherapy and also to treat manic or mixed episodes as monotherapy or an adjunct therapy with valproate or lithium. An oral atypical antipsychotic to be taken once daily, LYBALVI contains olanzapine, a proven antipsychotic agent, and a new chemical compound, samidorphan. Following the receipt of regulatory approval, Alkermes commercially launched the drug in October, 2021.
Mood Stabilizers Segment to Reach $1.2 Billion by 2026
Mood stabilizers are the psychiatric drugs that aid in controlling the swings between mania and depression. These medications are formulated to decrease the brain activity and are prescribed to restore neurochemical balance. In the global Mood Stabilizers segment, USA, Canada, Japan, China and Europe will drive the 2.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$873.6 Million will reach a projected size of US$1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$104.2 Million by the year 2026, while Latin America will expand at a 3.5% CAGR through the analysis period.
SELECT PLAYERS
AbbVie Inc.; Astellas Pharma Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Gedeon Richter Plc; GlaxoSmithKline Plc; H. Lundbeck A/S; Janssen Pharmaceutica N.V.; Johnson & Johnson Services, Inc.; Novartis International AG; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Validus Pharmaceuticals LLC
SEGMENTS
» Drug Class (Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs, Anti-Anxiety Drugs)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » UAE » Rest of Middle East » Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Bipolar Disorder Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
Bipolar Disorder Therapeutics - A Prelude |
Symptoms of Bipolar Disorder |
Mood Episode – A Major Symptom |
Manic Episode Vs Depressive Episode |
Causes of Bipolar Disorder |
Types of Bipolar Disorder |
Co-morbidities of Bipolar Disorder |
Segments |
Antipsychotic Drugs |
Anticonvulsants |
Mood Stabilizers |
Anti-Anxiety Drugs |
Select Drugs for Bipolar Disorder Treatment by Drug Class |
Impact of Covid-19 and a Looming Global Recession |
2020 Marked as a Year of Disruption & Transformation |
The Never-Ending “Race” Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond? |
COVID-19 Impact on Bipolar Disorder Therapeutics Market |
Global Market Analysis and Prospects |
Bipolar Disorder Therapeutics Market Set to Witness Rapid Growth |
Regional Market Analysis |
Treatment Analysis |
Anti-Psychotics |
Anti-Depressants |
Recent Market Activity |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Market Gains to Continue Amid Rising Prevalence of Bipolar Disorder |
Awareness Programs Augment Prospects |
Increasing R&D Activities Drive the Global Bipolar Disorder Therapeutics Market |
Technology Advancements Widen Addressable Market |
Social Inclusion of People with Mental Illnesses Augurs Well |
Online Self-Management Tools Improve Treatment Outcomes |
Increasing Product R&D, Approvals & Launches Support Market Expansion |
Side Effects of Bipolar Disorder Drugs |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Bipolar Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Mood Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Mood Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Mood Stabilizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Antidepressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Anti-anxiety Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
USA Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
CANADA |
Canada Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
JAPAN |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
Japan Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
CHINA |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
China Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
EUROPE |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Bipolar Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
FRANCE |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
France Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
GERMANY |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
Germany Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
ITALY |
Italy Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
UNITED KINGDOM |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
UK Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
ASIA-PACIFIC |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
AUSTRALIA |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E) |
Australia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
INDIA |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E) |
India Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
India Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
LATIN AMERICA |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E) |
Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027 |
Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
MIDDLE EAST |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E) |
Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027 |
Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
IRAN |
Iran Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
AFRICA |
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E) |
Africa Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 102 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com